Possession alone is rarely prosecuted, but the supply chain is unregulated
The right plan may depend on your health history, lab work, treatment goals, medication use, cycle length, response to treatment, and safety risks
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
Am J Physiol Gastrointest Liver Physiol 2009;296:G115166
Individual results vary based on starting weight, diet, exercise, and adherence to the medication schedule
Your PlexusDx clinician will monitor side effects at follow-up visits and adjust your dose pace if needed
